Similarly, upregulated expression of BTLA on CD8+ or CD4+ T cells or increased levels of soluble BTLA were associated with unfavorable prognosis for gallbladder cancer [26], diffuse large-B cell lymphoma [27], clear cell renal cell cancer [27], and prostate cancer patients [23]. The gene discussed is BTLA; the disease is clear cell renal carcinoma.